Broadcom vs American Express: Which Is Best?
Chip giant Broadcom Inc. (NASDAQ:AVGO) and card company American Express…
Sell
4
FHTX Quote, Financials, Valuation and Earnings
Last price:
$4.61
Seasonality move
:
-25.89%
Day range:
$4.55 - $4.85
52-week range:
$2.70 - $10.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.20x
P/B ratio:
--
Volume:
143.3K
Avg. volume:
172.2K
1-year change:
-26.82%
Market cap:
$262.4M
Revenue:
$34.2M
EPS (TTM):
-$1.92
Analysts' Opinion
-
Consensus RatingFoghorn Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.50, Foghorn Therapeutics has an estimated upside of 154.24% from its current price of $4.72.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $4.72.
Fair Value
-
According to the consensus of 5 analysts, Foghorn Therapeutics has 154.24% upside to fair value with a price target of $12.50 per share.
FHTX vs. S&P 500
-
Over the past 5 trading days, Foghorn Therapeutics has underperformed the S&P 500 by -1.72% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Foghorn Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Foghorn Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Foghorn Therapeutics reported revenues of $7.8M.
Earnings Growth
-
Foghorn Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Foghorn Therapeutics reported earnings per share of -$0.31.
Enterprise value:
-5M
EV / Invested capital:
--
Price / LTM sales:
9.20x
EV / EBIT:
--
EV / Revenue:
-0.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.05x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-30.59%
Net Income Margin (TTM):
-357.53%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-305.48%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $15.8M | $32.6M | $25.5M | $17.5M | $7.8M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$113.3M | -$114.3M | -$101.7M | -$17.1M | -$23.9M | |
| EBITDA | -$110.7M | -$110.9M | -$98.5M | -$16.2M | -$23.1M | |
| Diluted EPS | -$2.70 | -$2.46 | -$1.92 | -$0.34 | -$0.31 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $77.8M | $124M | $377.8M | $265.4M | $271.2M | |
| Total Assets | $142.4M | $186.1M | $433.9M | $313.4M | $308.4M | |
| Current Liabilities | $21.3M | $19.3M | $55.2M | $52M | $56.8M | |
| Total Liabilities | $275.8M | $105.1M | $409.6M | $370.8M | $336.7M | |
| Total Equity | -$133.3M | $81M | $24.3M | -$57.4M | -$28.3M | |
| Total Debt | $14.8M | $19.9M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $234.4M | -$119.5M | -$103.4M | -$27.2M | -$21M | |
| Cash From Investing | -$228.1M | $100.6M | -$14.8M | $38.4M | -$61.3M | |
| Cash From Financing | $23.5M | $1.6M | $105.6M | $1.4M | $1.1M | |
| Free Cash Flow | $233.4M | -$120.9M | -$103.9M | -$27.3M | -$21.3M | |
FHTX
Sector
Market Cap
$262.4M
$47.7M
Price % of 52-Week High
46.05%
46.05%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-26.82%
-33.33%
Beta (5-Year)
--
0.760
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$4.91
200-day SMA
Sell
Level
$6.80
Bollinger Bands (100)
Sell
Level
6.2 - 9
Chaikin Money Flow
Buy
Level
17.2M
20-day SMA
Sell
Level
$5.66
Relative Strength Index (RSI14)
Sell
Level
27.77
ADX Line
Sell
Level
12.07
Williams %R
Buy
Level
-86.7347
50-day SMA
Sell
Level
$7.16
MACD (12, 26)
Sell
Level
-0.75
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
29.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.2216)
Sell
CA Score
(Annual)
Level (-4.6433)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.1231)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Stock Forecast FAQ
In the current month, FHTX has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The FHTX average analyst price target in the past 3 months is $12.50.
-
Where Will Foghorn Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Foghorn Therapeutics share price will rise to $12.50 per share over the next 12 months.
-
What Do Analysts Say About Foghorn Therapeutics?
Analysts are divided on their view about Foghorn Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Foghorn Therapeutics is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Foghorn Therapeutics's Price Target?
The price target for Foghorn Therapeutics over the next 1-year time period is forecast to be $12.50 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is FHTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Foghorn Therapeutics is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of FHTX?
You can purchase shares of Foghorn Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Foghorn Therapeutics shares.
-
What Is The Foghorn Therapeutics Share Price Today?
Foghorn Therapeutics was last trading at $4.61 per share. This represents the most recent stock quote for Foghorn Therapeutics. Yesterday, Foghorn Therapeutics closed at $4.72 per share.
-
How To Buy Foghorn Therapeutics Stock Online?
In order to purchase Foghorn Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is Adobe Stock Dropping?
Why is Adobe stock dropping? A combination of underwhelming fiscal…
Why Is 3M Stock Going Up?
After a decade-long slump in new product introductions, the leading…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 41x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
77
FTAI alert for Jan 2
FTAI Aviation [FTAI] is up 0.29% over the past day.
Buy
56
QMCO alert for Jan 2
Quantum [QMCO] is up 0.83% over the past day.
Buy
78
BMA alert for Jan 2
Banco Macro SA [BMA] is up 12.94% over the past day.
